PTC Therapeutics Grants RSUs to New Employee, Strengthening Workforce Commitment and Talent Retention

PTC Therapeutics Reinforces Workforce Commitment with New Inducement Grant

PTC Therapeutics, Inc. announces the approval of 300 restricted stock units (RSUs) for a recently hired non-executive employee, effective January 2, 2026. This inducement grant is part of the company’s ongoing effort to attract and retain top talent as it continues to expand its innovative biopharmaceutical operations. Each RSU represents the right to receive one share of common stock upon vesting, which is contingent on the employee's sustained service at PTC. The decision to implement this grant aligns with Nasdaq Listing Rule 5635(c)(4), indicating PTC's commitment to adhering to regulatory standards in its employment practices.

The vesting schedule for the RSUs is structured over four years, with 25% vesting on each annual anniversary of the employee's hire date. This phased approach not only incentivizes long-term commitment from employees but also fosters a sense of ownership and accountability within the workforce. As PTC Therapeutics focuses on addressing the medical needs of patients with rare disorders, having a motivated and stable workforce is crucial for maintaining the momentum of its diverse pipeline of therapies. The company's strategy emphasizes the importance of human capital in delivering innovative solutions that resonate with patient needs.

This recent grant illustrates PTC’s broader strategy to enhance its talent acquisition efforts while reinforcing its mission of developing transformative therapies. By ensuring that employees feel valued and invested in the company's success, PTC positions itself to maximize its impact in the biopharmaceutical industry. The company’s emphasis on innovative medicines reflects its commitment to addressing unmet medical needs, underscoring the critical role that a robust workforce plays in achieving these goals. Interested stakeholders are encouraged to learn more about PTC’s initiatives and therapies through its official channels.

In addition to the RSU grant, PTC continues to advance its diverse pipeline of transformative therapies aimed at rare disorders, showcasing its scientific expertise and commercial capabilities. The company actively seeks to engage with both patients and investors, further solidifying its position in the biopharmaceutical landscape. For any inquiries, investors can reach out to Ellen Cavaleri, while media questions can be directed to Jeanine Clemente.